We conducted a systematic review and meta-analysis of randomized controlled trials to assess the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on microvascular endpoints in adult patients with type 2 diabetes. We included 60 studies with 60 077 patients. GLP-1 RAs marginally reduced urinary albumin-to-creatinine ratio compared with placebo or other antidiabetic agents (weighted mean difference − 2.55 mg/g; 95% confidence interval [CI] −4.37 to −0.73 and −5.52; −10.89 to −0.16, respectively) and had no clinically relevant effect on change in estimated glomerular filtration rate. Treatment with GLP-1 RAs did not increase incidence of diabetic retinopathy, macular oedema, retinal detachment and retinal haemorrhage, irrespective of comparator. Nevertheless, incidence of vitreous haemorrhage was higher in subjects treated with GLP-1 RAs compared with placebo (odds ratios 1.93; 95% CI 1.09 to 3.42). In conclusion, GLP-1 RAs are safe regarding nephropathy-and retinopathy-related outcomes. Caution may be warranted for incidence of vitreous haemorrhage. The low overall quality of evidence highlights the need for consistent assessment and reporting of microvascular endpoints in future trials. 
| INTRODUCTION
It is estimated that approximately one in three patients with diabetes will develop retinopathy 1 and one in four will develop nephropathy. 2 The presence of such microvascular complications impairs function and quality of life, and has been associated with increased risk of allcause mortality. 3 Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) decrease blood glucose by stimulating insulin secretion in a glucose-dependent manner. Although large, long-term randomized controlled trials (RCTs) showed either a neutral 4 or a favourable 5, 6 effect of GLP-1 RAs on cardiovascular outcomes in patients with type 2 diabetes (T2DM), their effect on microvascular endpoints remains controversial. On this ground, we conducted a systematic review and meta-analysis of RCTs to clarify the effect of GLP-1 RAs on renal and diabetic retinopathy-related outcomes in adults with T2DM.
| METHODS
We performed this systematic review and meta-analysis based on a prespecified protocol (PROSPERO registration No. CRD42018081578), and report our methods and results according to the PRISMA statement.
We searched MEDLINE, Embase and the Cochrane Library up to June 11, 2018 , as well as grey literature sources, without language restrictions. The detailed search strategy is available in Table S1 . Two reviewers (I. A., K. M.) independently screened titles and abstracts of all records, full texts of potentially eligible studies, extracted data from selected studies and assessed risk of bias. Any disagreements were resolved by consensus with a third reviewer (T. K.). Eligible studies were RCTs with treatment duration of at least 12 weeks comparing a GLP-1 RA with placebo or another antidiabetic agent in adults with T2DM. We made a post-hoc decision to exclude trials assessing albiglutide, following an official announcement of its discontinuation. 7 Further details of the eligibility criteria are available in Methods S1.
Our primary outcomes were change from baseline in urinary albumin-to-creatinine ratio (UACR, mg/g) and incidence of diabetic retinopathy. Secondary outcomes included change from baseline in estimated glomerular filtration rate (eGFR, mL/min/1.73 m 2 ) and in glycated haemoglobin (HbA1c, %), and incidence of macular oedema, retinal detachment, retinal haemorrhage, or vitreous haemorrhage.
For diabetic retinopathy-related outcomes, we preferably utilized data based on the Medical Dictionary for Regulatory Activities (MedDRA) coding, when available.
We used the revised Cochrane Collaborations' Rob2.0 risk of bias tool to assess the risk of bias of individual trials 8 , and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to summarize quality of evidence for our primary outcomes. 9 For continuous outcomes we calculated weighted mean differences (WMD) and 95% confidence intervals (CIs) using an inverse variance random effects model while for dichotomous outcomes we calculated odds ratios (ORs) and 95% CIs using the fixed effects Mantel-Haenszel approach, including trials with zero events in both arms. When necessary, we imputed data using appropriate methodology. 10, 11 Heterogeneity among studies was assessed with the I 2 statistic, with values > 50% representing substantial heterogeneity.
We performed separate analyses based on type of comparator (placebo or active comparator), and subgroup analyses based on type of GLP-1 RA and trial duration (less or more than 52 weeks). We also conducted sensitivity analyses including only trials at low overall risk of bias. Finally, we conducted post-hoc meta-regression analyses to investigate the relationship between change in HbA1c and incidence of diabetic retinopathy, and between trial duration and incidence of diabetic retinopathy or change in UACR. All analyses were conducted in RevMan 5.3 and STATA 13.1.
| RESULTS
The flow diagram of the study selection process is depicted in Figure S1 . A total of 117 records describing 60 RCTs (60 077 participants) were included in the systematic review and meta-analysis. Of these records, 1 was a pooled analysis for dulaglutide 12 (five RCTs).
The characteristics of the included studies and participants' baseline characteristics are summarized in Table S2 . All studies had a parallel group design except for one cross-over trial. Twenty-six trials assessed liraglutide, while exenatide, lixisenatide, dulaglutide and semaglutide were assessed in 9, 7, 10 and 8 trials, respectively. Study duration ranged from 12 weeks to 3.8 years, and was ≥52 weeks in 26 trials, while HbA1c levels at baseline ranged from 7.1% to 10.3%.
Pooled results for all outcomes are summarized in Table 1 , and subgroup analyses for individual GLP-1 RAs are presented in Table S3 .
GLP-1 RAs slightly reduced UACR compared with placebo (WMD −2.55 mg/g; 95% CI −4.37 to −0.73; I 2 = 45%) or other antidiabetic agents ( Figure S2 ). This was consistent both for trials with treatment duration <52 weeks against placebo (12 studies ; 95% CI −1.84 to −0.11; I 2 = 69%), while no effect was evident compared with active comparators (Table 1) . Similarly, GLP-1 RAs were not associated with an increase in the incidence of macular oedema, retinal detachment or retinal haemorrhage compared with placebo or other antidiabetic agents (Table 1) . However, treatment with GLP-1 RAs resulted in a higher incidence of vitreous haemorrhage in comparison with placebo (OR, 1.93; 95% CI 1.09 to 3.42; I 2 = 0%), a result mainly driven by the findings of the LEADER trial. GLP-1 RAs were also associated with a significant reduction of HbA1c compared with placebo or active comparators (Table 1) .
Finally, there was no association between change in HbA1c and incidence of diabetic retinopathy in meta-regression analyses of both placebo-controlled (P = 0.55) and active-controlled trials (P = 0.56).
Similarly, trial duration was not associated with incidence of diabetic retinopathy in placebo-controlled (P = 0.87) and active-controlled trials (P = 0.73), or with change in UACR (P = 0.62 and P = 0.35, respectively).
Overall risk of bias was high in most studies assessing change from baseline in UACR or incidence of diabetic retinopathy, mainly because of the high discontinuation rate, missing data, or the need for imputation of mean and standard deviation values (Tables S4 and S5 ).
Visual interpretation of the funnel plot or Egger's test (P = 0.54) did not reveal any evidence of small study effect. Based on the GRADE approach, overall quality of evidence was deemed low both for Notably, in a post-hoc analysis of the SUSTAIN-6 trial, no difference in the incidence rate for diabetic retinopathy complications was found between semaglutide and placebo trial arms in patients without preexisting diabetic retinopathy. 31 Finally, increased incidence of diabetic retinopathy-related events in the semaglutide arm could also be associated with the profound and rapid improvement of glycaemic control. 31 In contrast to previous meta-analyses, [32] [33] [34] we assessed renal microvascular complications utilizing outcomes used in clinical practice 35 , such as UACR and eGFR, and extracted data both on diabetic retinopathy and its individual components (macular oedema, retinal detachment, retinal haemorrhage and vitreous haemorrhage) from a larger pool of trials that incorporate the most up-to-date evidence.
Two meta-analyses by Dicembrini et al. 33 and Garguilo et al. Certain limitations should also be acknowledged. Almost none of the eligible studies were designed to assess microvascular endpoints, while our search identified a significant amount of potentially eligible records that did not report any data for the prespecified outcomes.
Additionally, in some analyses for dulaglutide we utilized data from a pooled analysis, because outcome data were not available in published reports of individual trials. We could not explore the effect of GLP-1
RAs on pre-existing diabetic retinopathy, because primary studies, except for a post-hoc analysis of the SUSTAIN-6 trial, did not report data separately for patients with pre-existing retinopathy. Similarly, no trial recruited exclusively patients with albuminuria at baseline or reported results for subgroups based on presence of albuminuria at baseline. Hence, our meta-analysis results cannot fully capture the association between baseline albuminuria and the effect of GLP-1
RAs on UACR reduction. Moreover, lack of formal adjudication in most studies may have led to misclassification of events, potentially undermining the validity of our findings. Finally, our results should be interpreted with caution, given the overall low quality of evidence for both primary outcomes.
In conclusion, our meta-analysis provides some reassurance that GLP-1 RAs are safe in terms of their effect on diabetic retinopathy and albuminuria or change in eGFR. Caution may be warranted for incidence of vitreous haemorrhage. It is also advised that clinicians closely monitor patients with pre-existing retinopathy who are treated with semaglutide, until further evidence clarifies the drug's effect on diabetic retinopathy complications. Under-reporting or inconsistent reporting of microvascular endpoints in primary RCTs can undermine the validity of our findings. It is therefore imperative for future trials to assess and report consistently defined, measured, and adjudicated microvascular outcomes.
